Compare COGT & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | ACEL |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 973.5M |
| IPO Year | 2018 | N/A |
| Metric | COGT | ACEL |
|---|---|---|
| Price | $37.93 | $11.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $30.00 | $14.00 |
| AVG Volume (30 Days) | ★ 2.5M | 477.7K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $1,307,029,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $4.29 |
| P/E Ratio | ★ N/A | $23.37 |
| Revenue Growth | N/A | ★ 7.97 |
| 52 Week Low | $3.72 | $9.02 |
| 52 Week High | $43.73 | $13.28 |
| Indicator | COGT | ACEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 66.83 |
| Support Level | $37.23 | $11.12 |
| Resistance Level | $40.59 | $11.72 |
| Average True Range (ATR) | 1.76 | 0.27 |
| MACD | -0.84 | 0.07 |
| Stochastic Oscillator | 14.03 | 90.55 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.